About this role
Are you an experienced clinical trials statistician with a passion for cancer research who enjoys working collaboratively to lead high-impact studies? We have an exciting opportunity for a Professor in Medical Statistics to be the Academic Lead for Clinical Trials in Oncology at the Sheffield Clinical Trials Research Unit (CTRU).
This role has been created following a prestigious multi-million-pound infrastructure grant. As the Academic Lead for Oncology Trials, you will provide senior oversight, leadership, and support for the development of a parallel stream of clinical trials in cancer within the CTRU.
Your work will have a direct impact on patient outcomes. You will lead the building of a sustainable pipeline of high-quality studies, ensuring that ambitious clinical ideas are translated into life-changing treatments.
From co-designing and overseeing complex oncology CTIMPs and navigating MHRA inspections to mentoring the next generation of triallists and clinical fellows, you will lead a portfolio that prioritises innovation and equity.
We are seeking a senior statistician with a proven track record of leadership within an oncology setting. You will be a strategic collaborator capable of bridging the gap between ambitious clinical questions and rigorous methodological excellence.
The ideal candidate will:
Hold a Post-graduate qualification and / or equivalent professional experience in Medical Statistics or a closely related discipline. Possess deep expertise in the design and analysis of Oncology CTIMPs, including an understanding of cancer-specific pharmacovigilance, UK regulatory frameworks, and MHRA requirements. Demonstrate a track record in Trial Development, with the ability to design efficient, high-impact studies—from early-phase dose-finding to large-scale Phase III trials. Show mastery of oncology-specific methodologies including but not limited to survival analysis and adaptive designs. Be a skilled communicator and grant-winner, capable of building strong relationships with Chief Investigators, funding bodies, and patient panels to secure major research investment.